Therapeutic Optimization of Anti-Tumor Drugs Based on Pharmacokinetics
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 1646
Special Issue Editors
Interests: cancer; anti-tumor drugs; pharmacokinetics; therapeutic drug monitoring; pharmacodynamics
Special Issue Information
Dear Colleagues,
The pharmacological therapy indicated for the treatment of malignant pathologies has seen a complex evolution, both in terms of the quantity and diversity of therapeutic targets and strategies available. From traditional cytotoxic chemotherapy to cell therapy and immunotherapy, the variety of alternatives must be accompanied by the development of strategies to individualize the treatments chosen for each patient.
Pharmacokinetics makes it possible to predict the time course of the drug in the body and various methodologies for individualizing therapy based on pharmacokinetic principles have been developed. Via therapeutic drug monitoring and applying Bayesian estimation methodologies to determine individual pharmacokinetic parameters, it is possible to establish an individualized dosage regimen that minimizes the risk of toxicity and increases therapeutic effectiveness.
This Special Issue aims to organize a set of original research and review articles, to guide future guidelines for the therapeutic optimization of drugs used in the treatment of malignant pathologies. This special edition also aims to suggest future lines of research to obtain more sustainable evidence on the above subject.
Dr. Paula Fresco
Dr. Joaquim António Faria Monteiro
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anti-cancer drugs
- pharmacokinetics
- therapeutic drug monitoring
- cancer
- populational pharmacokinetics models
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
